Core Insights - Oragenics, Inc. is a clinical-stage biotechnology company focused on brain-targeted therapeutics using proprietary intranasal delivery technology [3] - The company’s lead candidate, ONP-002, is in Phase IIa clinical development for treating concussion and mild traumatic brain injury (mTBI), which affects approximately 69 million people globally each year without any approved pharmacological treatment [3] - The company received an unqualified audit opinion from its independent accounting firm regarding its financial statements, which included a paragraph about its ability to continue as a going concern [1] Financial Information - The audited consolidated financial statements for the fiscal year ended December 31, 2025, were filed on March 16, 2026, with the Securities and Exchange Commission [1][2] - The announcement regarding the audit opinion is made in compliance with NYSE American LLC Company Guide Section 610(b) [1] Company Overview - Oragenics is exploring the expansion of its central nervous system (CNS) pipeline strategy through both internal development and strategic business development [3] - The company’s intranasal delivery platform aims to provide rapid, non-invasive delivery of therapeutics directly to the brain, bypassing the blood-brain barrier [3]

Core Insights - Oragenics, Inc. has completed the first site initiation visit for its Phase IIa clinical trial of ONP-002 in Australia, marking the start of clinical trial operations at the first of three planned sites [2][3] - The remaining two sites are undergoing final administrative reviews before patient enrollment can begin, with expectations for completion in the near term [3][4] - The Phase IIa trial aims to evaluate the safety, tolerability, and preliminary clinical signals of ONP-002 in patients with acute concussion and mild traumatic brain injury [5][7] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on brain-targeted therapeutics using proprietary intranasal delivery technology [11] - The lead candidate, ONP-002, is a first-in-class intranasal neurosteroid in Phase IIa development for treating concussion and mild traumatic brain injury, conditions affecting approximately 69 million people globally each year without approved pharmacological treatments [11] Clinical Trial Details - The Phase IIa trial is a randomized, placebo-controlled study with an enrollment target of 40 patients across three sites in Australia [9] - The primary endpoints include safety assessments, neurocognitive follow-up evaluations, and participant compliance/tolerability [9] - The first dose is to be administered within 12 hours of concussion onset, with the first site now operational and ready to enroll patients [9][6]

Core Insights - Oragenics, Inc. will present at the Sequire Investor Summit 2026, scheduled for January 20th-22nd, 2026, in San Juan, Puerto Rico [1] - The company aims to address the unmet medical need in concussion and mild traumatic brain injury with its lead candidate, ONP-002, which is advancing to Phase 2a clinical studies [2][3] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics using proprietary intranasal delivery technology [3] - The lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury, with ongoing Phase 2a trials in Australia and planned Phase IIb trials in the U.S. [3] - The intranasal delivery platform has potential applications for various neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders [3] Industry Context - Puerto Rico is an attractive location for investors due to its favorable tax benefits, making it home to many family offices and wealthy investors [2]